Defence Therapeutics Inc - DTCFF STOCK NEWS

Welcome to our dedicated news page for Defence Therapeutics (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on Defence Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Defence Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Defence Therapeutics's position in the market.

04/23/2024 03:15 AM

News

Defence's AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation

Rhea-AI Summary

Defence Therapeutics Inc. announces the success of its second-generation ARMTM anti-cancer vaccine, ARM-002TM, which has shown therapeutic effectiveness against pre-established melanoma when combined with an immune-checkpoint inhibitor. The vaccine utilizes AccuTOX® to induce protein aggregation in mesenchymal stromal cells, leading to potent antigen presentation. ARM-002TM is more potent than its predecessor, requiring 10x less protein for similar outcomes in both in vitro and in vivo studies. The vaccine is being tested on 'hard-to-treat' cancers like pancreatic, colon, and ovarian cancers, showing promising versatility and adaptability.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

04/17/2024 03:15 AM

News

Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth

Rhea-AI Summary

Defence Therapeutics partners with FMS Consult GmbH for financing strategy to support pipeline growth. The company's Accum® platform shows promise in cancer treatment.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

04/05/2024 06:00 PM

News

Defence Therapeutics Announces Warrant Terms Amendment

Rhea-AI Summary

Defence Therapeutics Inc. announces an amendment to the terms of 1,497,780 Class A Common share purchase warrants, extending the expiry date by 12 months and repricing the exercise price at $1.75 per share.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/26/2024 03:15 AM

News

Defence's Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine

Rhea-AI Summary

Defence Therapeutics Inc. announces successful testing of second-generation anti-cancer vaccine ARM-002TM with promising results in melanoma model. The vaccine shows an 80% complete response rate when combined with anti-PD-1 immune-checkpoint inhibitor. Defence reprogrammed MSCs using AccuTOX® to create a potent antigen presenting cell vaccine, reducing antigen preparation challenges. The company plans to expand testing to ovarian and pancreatic cancers and initiate Phase I trials targeting solid tumors.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

Tags

03/22/2024 06:30 PM

News

Defence Completes 2nd Tranche of Financing

Rhea-AI Summary

Defence Therapeutics Inc. announces the closing of the 2nd tranche of its non-brokered private placement, raising $600,000 for advancing preclinical and clinical programs.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/04/2024 03:15 AM

News

Defence Therapeutics Awarded Broad U.S. Patent Covering Its Pioneering Cancer-Killing AccuTOX(R) Technology

Rhea-AI Summary

Defence Therapeutics Inc. receives US patent for its breakthrough AccuTOX technology, providing market exclusivity until 2042. The technology induces cancer cell death and shows promising results in pre-clinical studies, leading to FDA approval for Phase I clinical trials in melanoma patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

02/29/2024 06:00 PM

News

Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update

Rhea-AI Summary

Defence Therapeutics Inc. announces a peer-reviewed study on its Accum®-E7 vaccine for cervical cancer treatment. The study, published in Cancer Science, highlights the vaccine's dual anti-cancer properties, prophylactic and therapeutic benefits, and safety profile. Defence also updates on a private placement offering.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

01/30/2024 08:00 PM

News

Defence Therapeutics Completes 1st Tranche of Financing

Rhea-AI Summary

Defence Therapeutics Inc. announces the closing of the 1st tranche of its non-brokered private placement, raising $850,500.00. The Company intends to use the net proceeds to advance its preclinical and clinical programs, including the Phase I clinical trial of Defence's AccuTOX administered intratumorally in patients with stage IIIB to IV melanoma, and for general working capital. The Offering consists of units priced at $1.50 per Unit, each containing one common share and one common share purchase warrant. The Company paid a cash finder's fee of $68,040.00 and issued Finder's Warrants to a certain qualified arm's length finder. All securities issued in connection with the Offering are subject to a statutory hold period of four months plus a day from their date of issue in accordance with applicable securities legislation.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-9.09%

Tags

01/19/2024 07:30 PM

News

Defence Financing

Rhea-AI Summary

Defence Therapeutics Inc. announces an amendment to its financing, conducting a non-brokered private placement of up to $2,250,000. The company will use the net proceeds to advance its preclinical and clinical programs, including the Phase I clinical trial of Defence's AccuTOX administered intratumorally in patients with stage IIIB to IV melanoma, and for general working capital.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

01/12/2024 07:15 PM

News

Defence Begins Trading on the OTCQB and Arranges Financing

Rhea-AI Summary

Defence Therapeutics Inc. announces a non-brokered private placement of up to $2,790,000 to advance its preclinical and clinical programs, including the Phase I clinical trial of Defence's AccuTOX®. The company's common shares have been upgraded to OTCQB, and are now trading under the symbol 'DTCFF'.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags